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Previewsmonocyte recruitment, transient cell abla-
tion, and modulation of the monocyte
subset prevalence.
An important question though remains:
arguably the mere increase in production
rate and shortening of bone marrow
residency will modify the monocytes;
however, does the inflammatory condi-
tion have a defined qualitative impact on
the blood monocyte compartment? Or
do circulating cells remain naive in the
chronically inflamed organism and undis-
tinguishable from the steady state until
they reach the inflamed tissue? These
and other questions should spur efforts
to extend the study of mouse models of
chronic disease and inflammation to the
blood, as—to finish with Goethe—‘‘Blood504 Immunity 32, April 23, 2010 ª2010 Elsevis a quite special kind of juice’’ (Faust I,
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In this issue of Immunity, Tsai et al. (2010) demonstrate that low-avidity autoantigen-specific regulatory CD8+
T cells can reverse ongoing autoimmune disease and provide insight into the mechanism by which this is
achieved.Type 1 diabetes (T1D) is an autoimmune
disease in which the pancreatic beta cells
are selectively destroyed by the immune
system. It is a disease of juvenile onset
and affected individuals rely on exoge-
nous insulin for their survival. An enor-
mous amount of effort hasbeen expended
to develop strategies to prevent onset of
this autoimmune condition as well as to
cure established disease.
One of the major goals in developing
therapies for autoimmune diseases such
as T1D has been to target autoreactive
T cells and generate specific immune
tolerance while sparing the ability to
respond to exogenous antigens. Although
antigen-specific tolerogenic approaches
have been shown to prevent onset of
autoimmune pathology in animal models,
they have proved to be relatively ineffec-tive in the treatment of ongoing disease.
It had been hoped that although epitope
and antigen spread inevitably occurred
with ongoing tissue destruction, antigen-
specific approaches might be successful
through inducing ‘‘infectious’’ or ‘‘bystan-
der’’ suppression. In terms of clinical
application targeting antigen specific au-
toreactive cells has thus far proved disap-
pointing. Current therapeutic approaches
with efficacy on established autoimmune
disease include the use of monoclonal
antibodies such as anti-CD3 and anti-
CD20 (Chatenoud, 2010; Pescovitz et al.,
2009). The availability of an antigen-
specific therapy would represent a major
advance.
By using dextran-coated iron oxide
nanoparticles bearing diabetes-related
peptide MHC complexes (pMHC-NP),Tsai et al. (2010) in this issue of Immunity
have shown that this may be achievable.
The composition of the nanoparticle is
key to its efficacy. Different nanoparticles
have previously been used to expand
antigen-specific effector cells in vaccine
design and to target tumors in cancer
therapy. This study highlights the poten-
tial to use nanoparticles to downregulate
immune responses and provides a poten-
tial therapeutic approach for the treat-
ment of human autoimmune disease.
The NOD mouse spontaneously de-
velops type 1 diabetes and has been
used not only to explore the etiology
of disease development but also to
develop therapeutic strategies (Kikutani
and Makino, 1992). Studies in this model
have shown that there is a need for both
CD4+ T cells and CD8+ T cells in disease
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Figure 1. Generation and Expansion of Autoantigen-Specific Regulatory CD8+ T Cells
Disease-relevant peptide MHC nanoparticle complexes mediate in vivo expansion of low-avidity
CD8+CD122+CXCR3+ T cell expressing high amounts of CD44 and CD62L (surface markers not depicted)
in the NOD mouse. These memory-regulatory CD8+ T cells do not express Foxp3 and are negative for
CCR7, CD69, and CD25, contain granzyme B, and secrete large amounts of IFN-g. Autoantigen-specific
regulatory CD8+ T cells can kill antigen presenting cells (APCs), presenting self-peptide in the presence of
costimulation. This results in an inhibition of autoreactive effector T cell proliferation. Perforin, but not Fas-
Fas-L interactions, plays a role in APC deletion. Pancreatic b cells would not be killed because they lack
costimulatory molecule expression. The important mechanistic role of IFN-g and IDO, involved in diabetes
prevention by these autoantigen-specific regulatory CD8+ T cells, will require further study. It is possible
that IFN-g induces IDO in the b cell or in DCs, making them tolerogenic.
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Previewsdevelopment (Phillips et al., 2009). Key
T cell activation events appear to occur
in the pancreatic draining lymph nodes
(PLNs) in which dendritic cells (DCs) pre-
sent b cell antigens to both T cell subsets
(Turley et al., 2003).
CD8+ regulatory T cells have had a
checkered history, but more recent stu-
dies have highlighted the potential for
this population to downregulate immune
responses. In this landmark study, Tsai
and colleagues have shown that nanopar-
ticles coated with the Kd containing a
mimotope peptide (NRP-V7) of an islet-
specific glucose-6-phosphatase catalytic
subunit-related protein (IGRP) peptide
(IGRP206-214) can be used to expand low-
avidity CD8+ T cells that not only inhibit
the development of type 1 diabetes in
NOD mice but also reverse established
disease (Figure 1). The effect was not
restricted to these NRP-V7-Kd-NPs given
that comparable results were obtained
with NPs coated with a Db-presenting
mimotope of another islet antigen. These
studies suggested that there were anti-
gen-experienced pools of CD8+ T cells
that were expanded by pMHC-NP treat-
ment. The requirement for the presence
of the autoantigenic epitope to induce
the CD8+ T cells was nicely demonstratedwith gene-targeted NOD mice that failed
to express the IGRP epitope and that
could not be rescued from diabetes
development by NRP-V7-Kd-NPs. Dia-
betes could, however, be reversed by
using NPs coated with another islet-
related peptide-MHC conjugate.
Analyses of mechanism revealed that
there seemed to be an expansion
of low-avidity CD8+CD44hiCD122+CCR7
CXCR3+CD62Lhi regulatory cells in the
diabetes-protected mice (Figure 1). Apart
from the expression of CD62L, these cells
bear some similarity with an effector and
memory CD8+ T cell population, identified
by Guarda et al., that downregulated
immune responses through selective
killing of antigen-carrying dendritic cells
(Guarda et al., 2007). Indeed, these low-
avidity autoantigen-specific CD8+ T cells
identified in this current study were
also shown to target antigen-expressing
DCs in the PLN. These low-avidity autoan-
tigen-specific CD8+ regulatory T cells
were able to suppress the proliferation of
effector CD8+ T cells in vitro and in the
PLN in vivo. Importantly, the response to
any antigen being copresented with islet
antigen by DCs was affected by these
T cells, providing a clue to the in vivo effi-
cacy of the pMHC-NPs at late stages ofImmunitydisease development, given that in the
PLN of a diabetic mouse, many islet
antigens would be presented. There was
no evidence of involvement of Foxp3-
expressing CD4+ or CD8+ T cells in this
regulation (Figure 1).
The Santamaria group generated TCR
transgenics with either high-avidity CD8+
T cells or low-avidity CD8+ T cells specific
for the IGRP peptide and showed that the
low-avidity cells behaved exactly like the
cells expanded by the NRP-V7-Kd-NPs.
These cells were able to prevent diabetes
induction in NOD.scid recipient mice by
effector T cells from diabetic donors. It
would seem likely that this was through
an effect on autoantigen presentation to
both CD4+ T cells as well as CD8+
T cells although this was not formally
shown. With regard to molecular mecha-
nism, the involvement of perforin, IFN-g,
and IDO was identified by using blocking
antibodies, inhibitors, and gene-targeted
mice with both in vitro and in vivo
approaches. Whereas the low-avidity
regulatory CD8+ T cells were shown to
express granzyme B and IFN-g, the
source of IDO remains to be clarified.
Work of others has clearly identified roles
for IDO in immune tolerance (Mellor and
Munn, 2004; Saxena et al., 2007). IFN-g
has been shown to induce IDO in a range
of cell types including dendritic cells and
macrophages, but it is also induced in
islets where it may serve to protect b cells
from destruction (Sarkar et al., 2007).
Any cell bearing IGRP or related pep-
tides and expressing costimulatory mole-
cules such as CD86 could be targeted
by theseCD8+T cells. Thus, B cells pulsed
with these peptides were eliminated
in vivo by these autoantigen-specific
regulatory CD8+ T cells. This is particularly
interesting in the context of the current
focus on B cell involvement in the patho-
genesis of T1D and the equivalent efficacy
of CD3 or CD20 directed therapy in this
autoimmune condition.
Could this approach be used to treat
humans with T1D? This was addressed
experimentally with NOD mice transgeni-
cally expressing HLA-A*0201 on a murine
MHC class I deficient background with
only A*0201-restricted CD8+ T cells in
the periphery. Treatment of either predia-
betic or diabetic HLA-A*0201-expressing
mice with NPs coated with relevant
islet antigen epitopes complexed with
the transgene-encoded MHC molecule32, April 23, 2010 ª2010 Elsevier Inc. 505
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Previewsprevented or reversed diabetes onset,
respectively. This study strongly suggests
that such a nanoparticle approach might
have efficacy in T1D patients. Given that
the authors found that there was recur-
rence of diabetes in 40%–50% of treated
diabetic mice within 20 weeks of the last
treatment, however, this might suggest
that repeated treatment protocols might
be needed.
In conclusion, this study highlights
a therapeutic strategy for the treatment
of autoimmune pathology involving the
recruitment and expansion of low-avid-
ity autoantigen-specific regulatory CD8+
T cells.506 Immunity 32, April 23, 2010 ª2010 ElsevREFERENCES
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